Breaking News

IPS Expands Irvine Ops

April 9, 2014

Aims to support long-term growth efforts

Integrated Project Services, Inc. (IPS) has expanded its operations with the opening of a new location in Irvine, CA.
 
“We are pleased to have a more permanent presence in this large and growing market,” saidDave Goswami, PE, chairman and chief executive officer, IPS. “Our recent growth and our leadership role in the biopharmaceutical sector have demanded us to be closer to our current and future West Coast clients. We see this as a natural step to maintain our current status in the Biopharmaceutical Community as well as support our long-term growth.”
 
“Irvine offers a strong base of current and potential clients located in Southern California with IPS reach to Northern California and throughout the Pacific Northwest,” said Patrick Bucklen, senior director, West Coast Operations and Principal.
 

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?